| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Nanna Thurmann Jørgensen, Trine Møller Erichsen, Morten Buus Jørgensen, Thomas Idorn, Bo Feldt-Rasmussen, Jens J Holst, Ulla Feldt-Rasmussen, Marianne Klos. Glucose metabolism, gut-brain hormones, and acromegaly treatment: an explorative single centre descriptive analysis. Pituitary. 2023-01-07. PMID:36609655. |
the objective of the study was to describe the differential effect of various treatment regimens on the secretion of glucose, insulin, glucagon, glucagon-like peptide-1 (glp-1), and glucose-dependent insulinotropic polypeptide (gip) in patients with acromegaly. |
2023-01-07 |
2023-08-14 |
Not clear |
| Alexandros Leonidas Liarakos, Anastasios Tentolouris, Alexandros Kokkinos, Ioanna Eleftheriadou, Nikolaos Tentolouri. Impact of Glucagon-like peptide 1 receptor agonists on peripheral arterial disease in people with diabetes mellitus: A narrative review. Journal of diabetes and its complications. vol 37. issue 2. 2023-01-07. PMID:36610322. |
glucagon-like peptide 1 (glp-1) receptor agonists (glp-1ras) are among the latest class of antidiabetic medications that stimulate insulin synthesis and secretion and have been used for the management of type 2 dm. |
2023-01-07 |
2023-08-14 |
Not clear |
| Jean-François Yale, Aude Roborel de Climens, Naresh Aggarwal, Terry Dex, Hertzel C Gerstein, Stewart Harris, Irene Hramiak, John Stewart, Lawrence A Leite. Ease of Use of the iGlarLixi SoloStar Pen from the LixiLan ONE CAN Pen Sub-Study: Questionnaire Findings from People Living with Type 2 Diabetes and Their HealthCare Providers. Diabetes therapy : research, treatment and education of diabetes and related disorders. 2022-12-27. PMID:36574199. |
for people with type 2 diabetes mellitus who do not achieve glycated hemoglobin a1c targets after treatment with basal insulin therapies, additional therapy with a glucagon-like peptide-1 receptor agonist (glp-1 ra) may be required. |
2022-12-27 |
2023-08-14 |
Not clear |
| Jean-François Yale, Aude Roborel de Climens, Naresh Aggarwal, Terry Dex, Hertzel C Gerstein, Stewart Harris, Irene Hramiak, John Stewart, Lawrence A Leite. Ease of Use of the iGlarLixi SoloStar Pen from the LixiLan ONE CAN Pen Sub-Study: Questionnaire Findings from People Living with Type 2 Diabetes and Their HealthCare Providers. Diabetes therapy : research, treatment and education of diabetes and related disorders. 2022-12-27. PMID:36574199. |
one option is to use a once-daily fixed-ratio combination (frc) of basal insulin and a glp-1 ra such as iglarlixi (which is composed of insulin glargine 100 u/ml and lixisenatide). |
2022-12-27 |
2023-08-14 |
Not clear |
| Jun Chen, Aihua Mei, Yingying Wei, Chunlei Li, Hang Qian, Xinwen Min, Handong Yang, Lingli Dong, Xiaoquan Rao, Jixin Zhon. GLP-1 receptor agonist as a modulator of innate immunity. Frontiers in immunology. vol 13. 2022-12-26. PMID:36569936. |
glucagon-like peptide-1 (glp-1) is a 30-amino acid hormone secreted by l cells in the distal ileum, colon, and pancreatic α cells, which participates in blood sugar regulation by promoting insulin release, reducing glucagon levels, delaying gastric emptying, increasing satiety, and reducing appetite. |
2022-12-26 |
2023-08-14 |
human |
| Jun Chen, Aihua Mei, Yingying Wei, Chunlei Li, Hang Qian, Xinwen Min, Handong Yang, Lingli Dong, Xiaoquan Rao, Jixin Zhon. GLP-1 receptor agonist as a modulator of innate immunity. Frontiers in immunology. vol 13. 2022-12-26. PMID:36569936. |
glp-1 specifically binds to the glucagon-like peptide-1 receptor (glp-1r) in the body, directly stimulating the secretion of insulin by pancreatic β-cells, promoting proliferation and differentiation, and inhibiting cell apoptosis, thereby exerting a glycemic lowering effect. |
2022-12-26 |
2023-08-14 |
human |
| André J Scheen, Pierre J Lefèbvr. Glucagon, from past to present: a century of intensive research and controversies. The lancet. Diabetes & endocrinology. 2022-12-25. PMID:36566754. |
this concept led to the design of different strategies targeting glucagon, among which glp-1 receptor (glp1r) agonists were a major breakthrough, and combination of inhibition of glucagon secretion with stimulation of insulin secretion (both in a glucose-dependent manner). |
2022-12-25 |
2023-08-14 |
Not clear |
| Hsuan-Wen Chou, Kai-Pi Cheng, An-Chi Lin, Hao-Chang Hung, Ching-Han Lin, Chih-Chen Wang, Hung-Tsung Wu, Horng-Yih O. Real-World Comparative Evaluation of Add-On Glucagon-like Peptide 1 Receptor Agonist in Type 2 Diabetes Treated with or without Insulin. Pharmaceuticals (Basel, Switzerland). vol 15. issue 12. 2022-12-23. PMID:36559020. |
the combination of glp-1 ra with basal insulin has been suggested in several clinical studies as a useful treatment for intensifying insulin therapy in t2d. |
2022-12-23 |
2023-08-14 |
Not clear |
| Hsuan-Wen Chou, Kai-Pi Cheng, An-Chi Lin, Hao-Chang Hung, Ching-Han Lin, Chih-Chen Wang, Hung-Tsung Wu, Horng-Yih O. Real-World Comparative Evaluation of Add-On Glucagon-like Peptide 1 Receptor Agonist in Type 2 Diabetes Treated with or without Insulin. Pharmaceuticals (Basel, Switzerland). vol 15. issue 12. 2022-12-23. PMID:36559020. |
however, there has been no real-world evidence study comparing the glycemic effects of glp-1 ras add-on to background treatment with and without insulin. |
2022-12-23 |
2023-08-14 |
Not clear |
| Hsuan-Wen Chou, Kai-Pi Cheng, An-Chi Lin, Hao-Chang Hung, Ching-Han Lin, Chih-Chen Wang, Hung-Tsung Wu, Horng-Yih O. Real-World Comparative Evaluation of Add-On Glucagon-like Peptide 1 Receptor Agonist in Type 2 Diabetes Treated with or without Insulin. Pharmaceuticals (Basel, Switzerland). vol 15. issue 12. 2022-12-23. PMID:36559020. |
the effectiveness of glp-1 ras on hba1c reduction was greater in insulin users than non-insulin users at 12 months (-1.17% vs. -0.76%; |
2022-12-23 |
2023-08-14 |
Not clear |
| Ioannis G Lempesis, Junli Liu, Maria Dalamag. The Metabolism open. vol 16. 2022-12-19. PMID:36530219. |
glp-1 and gip exert pleiotropic physiological actions, including enhancement of insulin secretion, glycemic and appetite control, cardioprotection, and adipose tissue improved function among others. |
2022-12-19 |
2023-08-14 |
Not clear |
| Е V Kashtanova, Yа V Polonskaya, V S Shramko, L V Shcherbakova, Е М Stakhneva, E V Sadovski, A N Spiridonov, Yu I Ragin. Associations of adipokines and metabolic hormones with low-density lipoprotein hypercholesterolemia in men and women under 45 years of age. Kardiologiia. vol 62. issue 11. 2022-12-15. PMID:36521046. |
concentrations of amylin, c-peptide, ghrelin, glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1 (glp-1), glucagon, interleukin 6, insulin, leptin, monocyte chemotactic protein 1 (mcp-1), pancreatic polypeptide (pp), peptide yy (pyy), tumor necrosis factor alpha (tnf-α), adiponectin, adipsin, lipocalin-2, plasminogen activator inhibitor 1 (pai-1), and resistin were measured by multiplex analysis (human metabolic hormone v3 and human adipokine panel 1 panels).results the groups differed in traditional cardiometabolic risk factors. |
2022-12-15 |
2023-08-14 |
human |
| George D Dimitriadis, Vaia Lambadiar. GLP-1 receptor agonists and SGLT-2 inhibitors as adjuncts to insulin in Type 1 diabetes: benefits and concerns. The Journal of clinical endocrinology and metabolism. 2022-12-12. PMID:36507904. |
glp-1 receptor agonists and sglt-2 inhibitors as adjuncts to insulin in type 1 diabetes: benefits and concerns. |
2022-12-12 |
2023-08-14 |
Not clear |
| Aya Yanagimoto, Yuji Matsui, Tohru Yamaguchi, Masanobu Hibi, Shigeru Kobayashi, Noriko Osak. Effects of Ingesting Both Catechins and Chlorogenic Acids on Glucose, Incretin, and Insulin Sensitivity in Healthy Men: A Randomized, Double-Blinded, Placebo-Controlled Crossover Trial. Nutrients. vol 14. issue 23. 2022-12-11. PMID:36501092. |
postprandial glucose, insulin, glucagon-like peptide-1 (glp-1), and glucose-dependent insulinotropic polypeptide (gip) responses were measured at baseline and after treatments. |
2022-12-11 |
2023-08-14 |
human |
| Aya Yanagimoto, Yuji Matsui, Tohru Yamaguchi, Masanobu Hibi, Shigeru Kobayashi, Noriko Osak. Effects of Ingesting Both Catechins and Chlorogenic Acids on Glucose, Incretin, and Insulin Sensitivity in Healthy Men: A Randomized, Double-Blinded, Placebo-Controlled Crossover Trial. Nutrients. vol 14. issue 23. 2022-12-11. PMID:36501092. |
consuming a combination of gtc and cca for three weeks significantly improved postprandial glycemic control, glp-1 response, and postprandial insulin sensitivity in healthy individuals and may be effective in preventing diabetes. |
2022-12-11 |
2023-08-14 |
human |
| Brian Rady, Jianying Liu, Hui Huang, Ivona Bakaj, Jenson Qi, S P Lee, Tonya Martin, Lisa Norquay, Mark Player, Alessandro Poca. A FFAR1 full agonist restores islet function in models of impaired glucose-stimulated insulin secretion and diabetic non-human primates. Frontiers in endocrinology. vol 13. 2022-12-09. PMID:36482991. |
recently, small molecule ffar1 agonists were discovered which bind to site-3, stimulating both intra-cellular calcium and camp, resulting in insulin and glucagon-like peptide-1 (glp-1) secretion. |
2022-12-09 |
2023-08-14 |
monkey |
| Michael M Swarbrick, Chad L Cox, James L Graham, Lotte B Knudsen, Kimber Stanhope, Kirsten Raun, Peter J Have. Growth hormone treatment does not augment the anti-diabetic effects of liraglutide in UCD-T2DM rats. Endocrinology, diabetes & metabolism. 2022-12-08. PMID:36480511. |
the incretin hormone glucagon-like peptide-1 (glp-1) slows gastric emptying, increases satiety and enhances insulin secretion. |
2022-12-08 |
2023-08-14 |
mouse |
| Xuekun Wang, Shiting Wei, Min Wang, Yao Xu, Weidi Hu, Mingyue Niu, Shiben Wang, Kang Lei, Lusha Ji, Renmin Liu, Guoxia J. Diphenyl ether derivatives as Novel GPR120 Agonists for the Treatment of Type 2 Diabetes mellitus. Chemistry & biodiversity. 2022-12-06. PMID:36471492. |
ffa-activated gpr120 could stimulate the release of glucagon-like peptide-1(glp-1), which can enhance the glucose-dependent secretion of insulin from pancreatic β cells. |
2022-12-06 |
2023-08-14 |
mouse |
| Yi-Hsuan Lin, Chia-Hung Lin, Yu-Yao Huang, Hsin-Yun Chen, An-Shun Tai, Shih-Chen Fu, Sheng-Hwu Hsieh, Jui-Hung Sun, Szu-Tah Chen, Sheng-Hsuan Li. Regimen comprising GLP-1 receptor agonist and basal insulin can decrease the effect of food on glycemic variability compared to a pre-mixed insulin regimen. European journal of medical research. vol 27. issue 1. 2022-12-03. PMID:36463197. |
regimen comprising glp-1 receptor agonist and basal insulin can decrease the effect of food on glycemic variability compared to a pre-mixed insulin regimen. |
2022-12-03 |
2023-08-14 |
Not clear |
| Yi-Hsuan Lin, Chia-Hung Lin, Yu-Yao Huang, Hsin-Yun Chen, An-Shun Tai, Shih-Chen Fu, Sheng-Hwu Hsieh, Jui-Hung Sun, Szu-Tah Chen, Sheng-Hsuan Li. Regimen comprising GLP-1 receptor agonist and basal insulin can decrease the effect of food on glycemic variability compared to a pre-mixed insulin regimen. European journal of medical research. vol 27. issue 1. 2022-12-03. PMID:36463197. |
this study compared the impact of insulin, glp-1 ra, and dietary components on gv using professional continuous glucose monitoring (cgm). |
2022-12-03 |
2023-08-14 |
Not clear |